Genmab A (GMAB) Long-Term Investments (2019 - 2026)

Genmab A's Long-Term Investments history runs 6 years deep, the most recent figure standing at $40.0 million for Q1 2026.

• Quarterly Long-Term Investments rose 33.33% year-over-year to $40.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (up 33.33% YoY) and the FY2025 annual result came in at $37.0 million, up 15.62% from the prior year.
• Long-Term Investments was $40.0 million for Q1 2026 at Genmab A, up from $37.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $40.0 million in Q1 2026 and bottomed at $20.0 million in Q4 2023.
• A 4-year average of $32.9 million and a median of $35.0 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2024 — Long-Term Investments surged 60.0% — and 2025, when it climbed 15.62%.
• Genmab A's Long-Term Investments stood at $20.0 million in 2023, then surged by 60.0% to $32.0 million in 2024, then increased by 15.62% to $37.0 million in 2025, then increased by 8.11% to $40.0 million in 2026.
• Business Quant data shows GMAB's Long-Term Investments at $40.0 million in Q1 2026, $37.0 million in Q4 2025, and $36.0 million in Q3 2025.